These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

337 related articles for article (PubMed ID: 16199884)

  • 1. Zinc finger transcription factors designed for bispecific coregulation of ErbB2 and ErbB3 receptors: insights into ErbB receptor biology.
    Lund CV; Popkov M; Magnenat L; Barbas CF
    Mol Cell Biol; 2005 Oct; 25(20):9082-91. PubMed ID: 16199884
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Flotillin depletion affects ErbB protein levels in different human breast cancer cells.
    Asp N; Pust S; Sandvig K
    Biochim Biophys Acta; 2014 Sep; 1843(9):1987-96. PubMed ID: 24747692
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Loss of Nrdp1 enhances ErbB2/ErbB3-dependent breast tumor cell growth.
    Yen L; Cao Z; Wu X; Ingalla ER; Baron C; Young LJ; Gregg JP; Cardiff RD; Borowsky AD; Sweeney C; Carraway KL
    Cancer Res; 2006 Dec; 66(23):11279-86. PubMed ID: 17145873
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The ErbB2/ErbB3 heterodimer functions as an oncogenic unit: ErbB2 requires ErbB3 to drive breast tumor cell proliferation.
    Holbro T; Beerli RR; Maurer F; Koziczak M; Barbas CF; Hynes NE
    Proc Natl Acad Sci U S A; 2003 Jul; 100(15):8933-8. PubMed ID: 12853564
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Estrogenic promotion of ErbB2 tyrosine kinase activity in mammary tumor cells requires activation of ErbB3 signaling.
    Liu B; Ordonez-Ercan D; Fan Z; Huang X; Edgerton SM; Yang X; Thor AD
    Mol Cancer Res; 2009 Nov; 7(11):1882-92. PubMed ID: 19861407
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Roles of mitogen-activated protein kinase and phosphoinositide 3'-kinase in ErbB2/ErbB3 coreceptor-mediated heregulin signaling.
    Vijapurkar U; Kim MS; Koland JG
    Exp Cell Res; 2003 Apr; 284(2):291-302. PubMed ID: 12651161
    [TBL] [Abstract][Full Text] [Related]  

  • 7. HDAC inhibitor vorinostat enhances the antitumor effect of gefitinib in squamous cell carcinoma of head and neck by modulating ErbB receptor expression and reverting EMT.
    Bruzzese F; Leone A; Rocco M; Carbone C; Piro G; Caraglia M; Di Gennaro E; Budillon A
    J Cell Physiol; 2011 Sep; 226(9):2378-90. PubMed ID: 21660961
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Widespread expression of ErbB2, ErbB3 and ErbB4 in non-human primate brain.
    Thompson M; Lauderdale S; Webster MJ; Chong VZ; McClintock B; Saunders R; Weickert CS
    Brain Res; 2007 Mar; 1139():95-109. PubMed ID: 17280647
    [TBL] [Abstract][Full Text] [Related]  

  • 9. c-Src modulates ErbB2 and ErbB3 heterocomplex formation and function.
    Ishizawar RC; Miyake T; Parsons SJ
    Oncogene; 2007 May; 26(24):3503-10. PubMed ID: 17173075
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dual Targeting of ERBB2/ERBB3 for the Treatment of SLC3A2-NRG1-Mediated Lung Cancer.
    Shin DH; Jo JY; Han JY
    Mol Cancer Ther; 2018 Sep; 17(9):2024-2033. PubMed ID: 29959202
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Expression of epidermal growth factor receptor or ErbB3 facilitates geldanamycin-induced down-regulation of ErbB2.
    Pedersen NM; Breen K; Rødland MS; Haslekås C; Stang E; Madshus IH
    Mol Cancer Res; 2009 Feb; 7(2):275-84. PubMed ID: 19208749
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Computational modeling of ERBB2-amplified breast cancer identifies combined ErbB2/3 blockade as superior to the combination of MEK and AKT inhibitors.
    Kirouac DC; Du JY; Lahdenranta J; Overland R; Yarar D; Paragas V; Pace E; McDonagh CF; Nielsen UB; Onsum MD
    Sci Signal; 2013 Aug; 6(288):ra68. PubMed ID: 23943608
    [TBL] [Abstract][Full Text] [Related]  

  • 13. AZD8931, an equipotent, reversible inhibitor of signaling by epidermal growth factor receptor, ERBB2 (HER2), and ERBB3: a unique agent for simultaneous ERBB receptor blockade in cancer.
    Hickinson DM; Klinowska T; Speake G; Vincent J; Trigwell C; Anderton J; Beck S; Marshall G; Davenport S; Callis R; Mills E; Grosios K; Smith P; Barlaam B; Wilkinson RW; Ogilvie D
    Clin Cancer Res; 2010 Feb; 16(4):1159-69. PubMed ID: 20145185
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Neuregulin-1 only induces trans-phosphorylation between ErbB receptor heterodimer partners.
    Li Z; Mei Y; Liu X; Zhou M
    Cell Signal; 2007 Mar; 19(3):466-71. PubMed ID: 16978839
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antitumor activity of a novel bispecific antibody that targets the ErbB2/ErbB3 oncogenic unit and inhibits heregulin-induced activation of ErbB3.
    McDonagh CF; Huhalov A; Harms BD; Adams S; Paragas V; Oyama S; Zhang B; Luus L; Overland R; Nguyen S; Gu J; Kohli N; Wallace M; Feldhaus MJ; Kudla AJ; Schoeberl B; Nielsen UB
    Mol Cancer Ther; 2012 Mar; 11(3):582-93. PubMed ID: 22248472
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Growth stimulation of non-small cell lung cancer cell lines by antibody against epidermal growth factor receptor promoting formation of ErbB2/ErbB3 heterodimers.
    Maegawa M; Takeuchi K; Funakoshi E; Kawasaki K; Nishio K; Shimizu N; Ito F
    Mol Cancer Res; 2007 Apr; 5(4):393-401. PubMed ID: 17426253
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Compensatory ErbB3/c-Src signaling enhances carcinoma cell survival to ionizing radiation.
    Contessa JN; Abell A; Mikkelsen RB; Valerie K; Schmidt-Ullrich RK
    Breast Cancer Res Treat; 2006 Jan; 95(1):17-27. PubMed ID: 16267617
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A naturally occurring secreted human ErbB3 receptor isoform inhibits heregulin-stimulated activation of ErbB2, ErbB3, and ErbB4.
    Lee H; Akita RW; Sliwkowski MX; Maihle NJ
    Cancer Res; 2001 Jun; 61(11):4467-73. PubMed ID: 11389077
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Silencing of ErbB3/ErbB2 signaling by immunoglobulin-like Necl-2.
    Kawano S; Ikeda W; Kishimoto M; Ogita H; Takai Y
    J Biol Chem; 2009 Aug; 284(35):23793-805. PubMed ID: 19561085
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Selective hormone-dependent repression of estrogen receptor beta by a p38-activated ErbB2/ErbB3 pathway.
    St-Laurent V; Sanchez M; Charbonneau C; Tremblay A
    J Steroid Biochem Mol Biol; 2005 Feb; 94(1-3):23-37. PubMed ID: 15862947
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.